Trials / Active Not Recruiting
Active Not RecruitingNCT05122559
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 98 (estimated)
- Sponsor
- Emmanuelle Waubant, MD PhD · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-acetyl cysteine | N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection. |
| DRUG | Placebo | Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF |
Timeline
- Start date
- 2022-02-16
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2021-11-16
- Last updated
- 2026-03-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05122559. Inclusion in this directory is not an endorsement.